{"title":"Murine Models of Pancreatitis Leading to the Development of Pancreatic Cancer.","authors":"Ana S Leal, Karen T Liby","doi":"10.1002/cpph.48","DOIUrl":null,"url":null,"abstract":"<p><p>Chronic or repeated episodes of acute pancreatic inflammation, or pancreatitis, are risk factors for the development of pancreatic cancer. Pancreatic cancer is characterized by a strong fibro-inflammatory tumor microenvironment. In pancreatitis, the same fibro-inflammatory reaction is observed concurrently with a loss of normal pancreatic cells. Mouse models are commonly employed to study the progression of pancreatitis and pancreatic cancer, with genetic and pharmacological tools used to elucidate cellular and acellular interactions within pancreatic tumors. Described in this article is a protocol for using Kras<sup>G12D</sup> ; Pdx1-Cre (KC) mice stimulated with caerulein, a small oligopeptide that increases secretion of digestive enzymes, as a model for pancreatitis. KRAS is mutated in 90-95% of the tumors in patients with pancreatic cancer. The combination of this mutation with an inflammatory stimulus accelerates the development of pancreatic cancer. The protocol detailed in this report follows the progression of disease in KC mice from pancreatic intraepithelial neoplasias to invasive pancreatic adenocarcinoma. © 2018 by John Wiley & Sons, Inc.</p>","PeriodicalId":10871,"journal":{"name":"Current Protocols in Pharmacology","volume":"83 1","pages":"e48"},"PeriodicalIF":0.0000,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/cpph.48","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Protocols in Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/cpph.48","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/10/16 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 6
Abstract
Chronic or repeated episodes of acute pancreatic inflammation, or pancreatitis, are risk factors for the development of pancreatic cancer. Pancreatic cancer is characterized by a strong fibro-inflammatory tumor microenvironment. In pancreatitis, the same fibro-inflammatory reaction is observed concurrently with a loss of normal pancreatic cells. Mouse models are commonly employed to study the progression of pancreatitis and pancreatic cancer, with genetic and pharmacological tools used to elucidate cellular and acellular interactions within pancreatic tumors. Described in this article is a protocol for using KrasG12D ; Pdx1-Cre (KC) mice stimulated with caerulein, a small oligopeptide that increases secretion of digestive enzymes, as a model for pancreatitis. KRAS is mutated in 90-95% of the tumors in patients with pancreatic cancer. The combination of this mutation with an inflammatory stimulus accelerates the development of pancreatic cancer. The protocol detailed in this report follows the progression of disease in KC mice from pancreatic intraepithelial neoplasias to invasive pancreatic adenocarcinoma. © 2018 by John Wiley & Sons, Inc.
小鼠胰腺炎模型导致胰腺癌的发展。
慢性或反复发作的急性胰腺炎症,或胰腺炎,是胰腺癌发展的危险因素。胰腺癌的特点是具有强烈的纤维炎性肿瘤微环境。在胰腺炎中,同样的纤维炎症反应与正常胰腺细胞的损失同时发生。小鼠模型通常用于研究胰腺炎和胰腺癌的进展,遗传和药理学工具用于阐明胰腺肿瘤内细胞和非细胞相互作用。本文描述的是KrasG12D的使用协议;用小蛋白刺激Pdx1-Cre (KC)小鼠作为胰腺炎模型,小蛋白是一种增加消化酶分泌的小寡肽。90-95%的胰腺癌患者肿瘤中KRAS发生突变。这种突变与炎症刺激的结合加速了胰腺癌的发展。本报告详细介绍了KC小鼠从胰腺上皮内瘤变到浸润性胰腺腺癌的疾病进展。©2018 by John Wiley & Sons, Inc。
本文章由计算机程序翻译,如有差异,请以英文原文为准。